Tonix Pharmaceuticals Holding Corp. TNXP
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
-0.37
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $13.1M | -$124.0M | — | -$103.2M | $245.2M |
| 2024 | $10.1M | -$130.0M | — | -$61.0M | $139.6M |
| 2023 | $7.8M | -$116.7M | — | -$109.9M | $105.5M |
| 2022 | — | -$110.2M | — | -$146.2M | $207.2M |
| 2021 | — | -$92.3M | — | -$110.9M | $218.7M |
| 2020 | — | -$50.5M | — | -$57.1M | $87.6M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Taylor Carolyn E. | director | 2026-06-12 | Buy | 1,415 | $10.55 |
| LEDERMAN SETH | Chief Executive Officer | 2026-06-09 | Buy | 5,000 | $11.79 |
| Stillwell Richard Newcomb | director | 2026-06-08 | Buy | 5,000 | $11.65 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -0.37 (distress)
- Working capital / assets 0.715
- Retained earnings / assets -3.084
- EBIT / assets -0.454
- Equity / liabilities 7.656
Source: SEC EDGAR filings · CIK 0001430306 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.